Universal Beteiligungs und Servicegesellschaft mbH Has $29.21 Million Stock Position in Guardant Health, Inc. $GH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH trimmed its stake in Guardant Health by 4.6%, selling 13,995 shares to hold 287,454 shares worth about $29.21 million (0.23% ownership) per its latest 13F filing.
• Guardant Health missed on EPS, reporting ($0.50) versus an expected ($0.43), but beat revenue estimates with $281.27 million, a 39.4% year‑over‑year increase.
• Analysts remain largely positive after recent upgrades — 20 Buys, 1 Hold, 1 Sell — with a consensus price target of roughly $125.20.

Universal Beteiligungs und Servicegesellschaft mbH reduced its stake in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 287,454 shares of the company's stock after selling 13,995 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.23% of Guardant Health worth $29,214,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth $27,000. Chesapeake Asset Management LLC acquired a new stake in shares of Guardant Health during the 4th quarter worth $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Guardant Health during the 4th quarter worth $31,000. Sound Income Strategies LLC acquired a new stake in shares of Guardant Health during the 3rd quarter worth $38,000. Finally, First Pacific Financial acquired a new stake in shares of Guardant Health during the 4th quarter worth $43,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Down 1.9%

Guardant Health stock opened at $87.87 on Friday. The company has a market capitalization of $11.53 billion, a PE ratio of -26.55 and a beta of 1.64. Guardant Health, Inc. has a 12 month low of $36.36 and a 12 month high of $120.74. The stock has a 50-day moving average price of $91.30 and a two-hundred day moving average price of $95.15.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to analysts' expectations of $269.74 million. The company's revenue was up 39.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.62) EPS. As a group, analysts predict that Guardant Health, Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In related news, insider Terilyn J. Monroe sold 3,832 shares of Guardant Health stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider directly owned 20,990 shares of the company's stock, valued at $1,945,353.20. The trade was a 15.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 3,000 shares of Guardant Health stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $87.04, for a total value of $261,120.00. Following the completion of the transaction, the chief financial officer directly owned 43,601 shares in the company, valued at approximately $3,795,031.04. This represents a 6.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 8,596 shares of company stock valued at $775,767 over the last three months. Company insiders own 6.10% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Canaccord Genuity Group upped their price objective on Guardant Health from $125.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Wells Fargo & Company upped their price objective on Guardant Health from $120.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, February 20th. TD Cowen upped their price objective on Guardant Health from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Stifel Nicolaus upped their price objective on Guardant Health from $120.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Finally, Citigroup upped their price objective on Guardant Health from $135.00 to $150.00 and gave the stock a "buy" rating in a research report on Friday, February 20th. Twenty equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $125.20.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.